WS
HQL

Wedbush Securities’s abrdn Life Sciences Investors HQL Stock Holding History

Wedbush Securities’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$319K Buy
15,960
+5,360
+51% +$94.7K 0.01% 912
2026
Q1 		$172K Hold
10,600
– – 0.01% 1158
2025
Q4 		$178K Sell
10,600
-350
-3% -$5.88K 0.01% 1133
2025
Q3 		$170K Sell
10,950
-1,000
-8% -$13.7K 0.01% 1091
2025
Q2 		$153K Buy
11,950
+200
+2% +$2.47K 0.01% 1082
2025
Q1 		$149K Buy
+11,750
New +$159K 0.01% 1037
2024
Q4 		– Sell
-16,273
Closed -$245K – 1165
2024
Q3 		$245K Sell
16,273
-400
-2% -$6.05K 0.01% 904
2024
Q2 		$236K Buy
16,673
+1,261
+8% +$17.1K 0.01% 987
2024
Q1 		$210K Sell
15,412
-4,700
-23% -$65K 0.01% 1070
2023
Q4 		$271K Sell
20,112
-2,624
-12% -$32.3K 0.01% 814
2023
Q3 		$284K Buy
22,736
+3,000
+15% +$39.5K 0.01% 754
2023
Q2 		$267K Buy
19,736
+1,724
+10% +$23.8K 0.01% 810
2023
Q1 		$251K Buy
18,012
+1,250
+7% +$17.9K 0.01% 822
2022
Q4 		$238K Buy
16,762
+2,450
+17% +$35.5K 0.01% 834
2022
Q3 		$196K Buy
14,312
+318
+2% +$4.75K 0.01% 902
2022
Q2 		$199K Buy
13,994
+824
+6% +$12.4K 0.01% 929
2022
Q1 		$218K Buy
13,170
+2,975
+29% +$51.2K 0.01% 948
2021
Q4 		$196K Buy
10,195
+109
+1% +$2.19K 0.01% 1062
2021
Q3 		$210K Sell
10,086
-17
-0.2% -$364 0.01% 1042
2021
Q2 		$217K Buy
+10,103
New +$204K 0.01% 1026
2019
Q2 		– Sell
-10,913
Closed -$187K – 1011
2019
Q1 		$187K Buy
+10,913
New +$188K 0.02% 792
2018
Q4 		– Sell
-11,707
Closed -$239K – 882
2018
Q3 		$239K Buy
+11,707
New +$233K 0.03% 686
2016
Q3 		– Sell
-10,104
Closed -$174K – 842
2016
Q2 		$174K Buy
+10,104
New +$186K 0.03% 648
2016
Q1 		– Sell
-12,059
Closed -$285K – 775
2015
Q4 		$285K Buy
12,059
+1,601
+15% +$39.7K 0.05% 426
2015
Q3 		$235K Sell
10,458
-589
-5% -$16.5K 0.05% 465
2015
Q2 		$312K Buy
11,047
+2,105
+24% +$58.3K 0.06% 412
2015
Q1 		$247K Buy
+8,942
New +$244K 0.04% 495

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
NIM
Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
AAM
Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return
1WA
180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

Wedbush Securities's HQL Position: Q2 2026 in Review

Wedbush Securities increased its abrdn Life Sciences Investors (HQL) stake by 51% in Q2 2026, buying an estimated $94.7K and bringing the position to 15,960 shares worth $319K. The position accounts for 0.01% of the portfolio, ranked #912.

Wedbush Securities first reported a position in HQL in Q1 2015 and has held it in 27 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

  • Wedbush Securities held 15,960 shares of abrdn Life Sciences Investors worth $319K as of Q2 2026.
  • Wedbush Securities bought 5,360 abrdn Life Sciences Investors shares in Q2 2026, an estimated $94.7K.
  • abrdn Life Sciences Investors made up 0.01% of Wedbush Securities's portfolio in Q2 2026, its #912 holding.
  • Wedbush Securities first reported a position in abrdn Life Sciences Investors in Q1 2015 and has held it in 27 quarters since.
  • 83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on Wedbush Securities's 13F filing for Q2 2026, filed 28 Jul 2026.